期刊文献+

高分辨率熔解曲线分析技术检测血清游离DNA的EGFR基因突变 被引量:1

High resolution melting analysis for EGFR mutations in plasma free DNA
下载PDF
导出
摘要 目的利用高分辨率熔解曲线分析技术(high resolution melting,HRM)检测石蜡包埋组织和血清游离DNA的表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变,分析两者之间的关系,并探讨其临床应用价值。方法利用HRM技术检测EGFR基因突变的方法,检测200例非小细胞肺癌患者石蜡包埋标本和200例相应的血清游离DNA,并将二者结果进行比较分析。结果HRM法检测非小细胞肺癌患者石蜡包埋组织DNA的EGFR基因突变总检出率为43.5%,血清游离DNA的EGFR基因突变总检出率为25.0%,HRM法检测血清游离DNA的EGFR基因突变与检测石蜡包埋组织DNA的EGFR基因突变相比,敏感性为57.5%,特异性为100%。结论 HRM法检测血清游离DNA的EGFR基因突变为无法获取肿瘤组织标本的患者提供了新的检测机会。 Objective To detect EGFR mutations using FFPE tissues and plasma free DNA by HRM analysis and to evaluate its clinical application value. Methods Formalin-fixed paraffin-embedded tissues and plasma free DNA of 200 NSCLC patients were detected by HRM analysis,the results were analyzed and compared accordingly. Results For FFPE tissues,the total EGFR mutation rate was 43. 5% detected by HRM,and for plasma free DNA,the EGFR mutation rate was 25. 0%. The sensitivity of HRM assays in plasma free DNA samples was 57. 5%,the specificity of HRM assays in plasma free DNA samples was 100%. Conclusions HRM for EGFR mutations in plasma free DNA could be accepted as an option for patients who are unable to obtain tumor tissue specimens in the diagnostic or screening setting.
出处 《中国肿瘤外科杂志》 CAS 2016年第1期36-39,共4页 Chinese Journal of Surgical Oncology
基金 江苏省肿瘤医院院内基金(ZQ201205 ZQ201206 ZM201203)
关键词 高分辨率熔解曲线分析技术 EGFR基因突变 血清游离DNA High resolution melting analysis EGFR mutation Plasma free DNA
  • 相关文献

参考文献9

  • 1HERBST R S, HEYMACH J V, LIPPMAN S M. Lung cancer[ J]. N Engl J Med, 2008,359(13) : 1367-1380.
  • 2武晓楠.表皮生长因子受体基因在多种肿瘤中的突变情况及临床意义[J].中国全科医学,2008,11(13):1197-1201. 被引量:13
  • 3DO H, DOBROVIC A. Limited copy number-high resolution melt- ing (LCN-HRM) enables the detection and identification by se- quencing of low level mutations in cancer biopsies[J]. Mol Canc- er, 2009, 8:82-92.
  • 4王卓,井昶雯,曹海霞,马蓉,吴建中.高分辨率熔解曲线分析技术检测EGFR基因突变方法的建立及其初步临床应用[J].中国肿瘤外科杂志,2014,6(4):236-239. 被引量:6
  • 5PRENZEL N, FISCHER O M, STREIT S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification [ J ]. Endocr Relat Cancer,2001,8 (1) :11-31.
  • 6SHARMA S V, BELL D W, SETTLEMAN J, et al. Epidermal growth factor receptor mutations in lung cancer[ J]. Nat Rev Canc- er, 2007,7 (3):169-181.
  • 7JIANG B, LIU F, YANG L, et al. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched se- quencing in Chinese patients with advanced non-small cell lung cancer[J]. J Int Med Res,2011,39(4) :1392-1401.
  • 8KIMURA H, KASAHARA K, SHIBATA K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy- naive non-small cell lung cancer [ J ]. J Thorac Oncol, 2006, 1 (3) :260-267.
  • 9KUANG Y, ROGERS A,YEAP B Y, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer[ J]. Clin Cancer Res,2009,15 (8) :2630-2636.

二级参考文献62

  • 1PM Harari. Epidermal growth factor receptor inhibition strategies in oncology [ J ]. Endocrine- Related Cancer, 2004, 11: 689- 708.
  • 2Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis [ J ]. Eur J Cancer, 2001, 37 (suppl4): S9-S15.
  • 3Paez JG, Janne PA, Lee JC, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy [ J ]. Science, 2004, 304 (5676): 1497-1500.
  • 4Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non - Small - Cell Lung Cancer to Gefitinib [J]. N Engl J Med, 350, 21:2129 - 2139.
  • 5Helfrich BA, Raben D, Varella - Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, lressa) in non - small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels [ J]. Clin Cancer Res, 2006, 12 (23): 7117-7125.
  • 6Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloal- veolar carcinoma subtype, predict response to erlotinib [ J ]. J Clin Oncol, 2008, 26 (9) : 1472 - 1478.
  • 7Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer [J]. Nat Rev Cancer, 2007, 7: 169-181.
  • 8Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and areassociated with sensitivity of tumors to gefitinib and erlotinib [ J ]. Proc Nail Acad Sci, 2004, 101: 13306-13311.
  • 9Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non - small -cell lungcancer [J]. J Clin Oncol, 2007, 25 (5) : 587 -595.
  • 10Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients [ J ]. Int J Cancer, 2006, 118 (1): 180-184.

共引文献17

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部